Medeon Biodesign (ROCO:6499) EBIT: NT$-716.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6499 Medeon Biodesign Inc ROCO:6499
68 GF Score
Price NT$69.80
GF Value NT$107.08
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medeon Biodesign EBIT?

Medeon Biodesign ROCO:6499 -1.69% 68 EBIT is NT$-716.0 Mil as of Dec. 2025. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.08 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Medeon Biodesign's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$-153.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-716.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medeon Biodesign's annualized ROC % for the quarter that ended in Dec. 2025 was -123.18%. Medeon Biodesign's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -221.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medeon Biodesign's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -12.27%.


Medeon Biodesign  (ROCO:6499) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medeon Biodesign's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-640.404 * ( 1 - 0.11% )/( (530.866 + 507.778)/ 2 )
=-639.6995556/519.322
=-123.18 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1519.559 - 121.634 - ( 937.367 - max(0, 174.263 - 1041.322+937.367))
=530.866

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1779.793 - 110.824 - ( 1219.859 - max(0, 160.957 - 1322.148+1219.859))
=507.778

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Medeon Biodesign's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-615.556/( ( (286.484 + max(-31.796, 0)) + (268.255 + max(-21.245, 0)) )/ 2 )
=-615.556/( ( 286.484 + 268.255 )/ 2 )
=-615.556/277.3695
=-221.93 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(46.844 + 25.469 + 28.479) - (121.634 + 0 + 10.954)
=-31.796

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(39.263 + 24.84 + 34.22) - (110.824 + 0 + 8.744)
=-21.245

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medeon Biodesign's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-716.011/5837.300
=-12.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medeon Biodesign EBIT Related Terms


Medeon Biodesign EBIT Historical Data

* Premium members only.

The historical data trend for Medeon Biodesign's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeon Biodesign EBIT Chart

Medeon Biodesign Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -512.88 -433.90 -1,224.04 -853.09 -716.01

Medeon Biodesign Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -224.70 -189.73 -187.29 -185.11 -153.89

ROCO:6499 vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medeon Biodesign EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's EV-to-EBIT falls into.


ROCO:6499
68GF Score
Medeon Biodesign Inc ROCO:6499
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medeon Biodesign EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-716.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-716.0 Mil mean?
Medeon Biodesign (ROCO:6499) has a EBIT of NT$-716.0 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medeon Biodesign.
Is Medeon Biodesign's EBIT too high?
Medeon Biodesign's current EBIT is NT$-716.0 Mil. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's EBIT compare to ISRG and BDX?
Medeon Biodesign's EBIT of NT$-716.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medeon Biodesign. Medeon Biodesign's current EBIT is NT$-716.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.08, compared to a current price of NT$69.80 — trading 34.8% below its estimated fair value. The current EBIT is NT$-716.0 Mil. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current EBIT is NT$-716.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?

Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued. The current stock price of NT$69.80 is trading 34.8% below its estimated GF Value™ of NT$107.08. GuruFocus considers Medeon Biodesign to be Significantly Undervalued.

Key valuation signals for ROCO:6499:

  • EBIT: NT$-716.0 Mil
  • GF Value™: NT$107.08 vs. price of NT$69.80 (34.8% below fair value)
  • GF Score™: 68/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medeon Biodesign Business Description

Address No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
68GF Score

Get the complete analysis for ROCO:6499

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.80
Price
NT$107.08
GF Value